CINP-AsCNP 2025 - Program

Back

Data Blitz Session
Session Room 216

Tuesday, June 17, 12:15 PM – 01:15 PM

Data Blitz 5: Psychedelic/ketamine-related

Chair: Argel Aguilar-Valles (Ottawa, Canada)

The mGluR2/3 antagonist enhances the behavioral and cellular antidepressant-like effects of psilocybin and scopolamine

Speaker: Andrzej Pilc (Krakow, Poland)

12:15 PM – 12:21 PM
6 min

Mapping neuronal ensemble activity in the mouse prefrontal cortex during motivational control of behavior following ketamine treatment

Speaker: Jess Nithianantharajah (Parkville Victoria, Australia)

12:21 PM – 12:27 PM
6 min

Psilocybin assisted psychotherapy for obsessive compulsive disorder, body dysmorphic disorder, and anorexia nervosa: study protocol

Speaker: Nicola Acevedo (Melbourne, Australia)

12:27 PM – 12:33 PM
6 min

Elucidating NMDA Receptor Hypofunction using Simultaneous EEG-fMRI Measures of Ketamine-Induced Neural Dynamics

Speaker: Moritz Haaf (Boston, United States)

12:33 PM – 12:39 PM
6 min

Psilocybin with Psychotherapeutic Support for Treatment-Resistant Depression: A Pilot Clinical Trial

Speaker: Sally Meikle (Melbourne, Australia)

12:39 PM – 12:45 PM
6 min

Using Classification and Regression Tree Modelling to Investigate Low-Dose Ketamine's Effect on Remission of Suicidal Symptoms Among Patients with Treatment-Resistant Depression and Strong Suicidal Thought

Speaker: Ping Chung Wu (Taipei, Taiwan)

12:45 PM – 12:51 PM
6 min

Therapeutic memory reconsolidation as a treatment for substance use disorders and how psychedelics are facilitating this intervention: The UNITy Study

Speaker: Shelan Ofori (London, United Kingdom)

12:51 PM – 12:57 PM
6 min

Acute and chronic psilocybin in mouse models of psychiatric disorders

Speaker: Thibault Renoir (Melbourne, Australia)

12:57 PM – 01:03 PM
6 min

Safety and ethical considerations for psychedelic assisted psychotherapy (PAP)

Speaker: Susan Rossell (Melbourne, Australia)

01:03 PM – 01:09 PM
6 min

Discussion, Q&A

01:09 PM – 01:15 PM
6 min